Adicet Bio, Inc. (ACET) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.35
↑+184% vs avg
5yr avg: 0.12
30Y Low0.0·High1.1
ROE
↓
-67.6%
↑-36% vs avg
5yr avg: -49.7%
30Y Low-148%·High12%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.8·High10.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACET Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Adicet Bio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $75M | $58M | $5M | $5M | $23M | $34M | $6M | $12M | $112M | — | — |
| Enterprise Value | $51M | $34M | $-33978031 | $-133702617 | $-213679389 | $-222765420 | $-56263139 | $1M | $108M | — | — |
| P/E Ratio → | -0.47 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 0.92 | 3.48 | 0.36 | 12.16 | 13.74 | — | — |
| P/B Ratio | 0.35 | 0.36 | 0.03 | 0.03 | 0.08 | 0.11 | 0.06 | — | 1.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACET EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | -8.55 | -22.89 | -3.14 | 1.50 | 13.26 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ACET Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -67.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 99.0% | 100.0% | 24.8% |
| Operating Margin | — | — | — | — | -290.3% | -631.4% | -218.9% | -3154.6% | -182.9% | -3.4% | -0.0% |
| Net Profit Margin | — | — | — | — | -279.3% | -637.2% | -204.9% | -2827.9% | -113.7% | -6.0% | -0.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -67.6% | -67.6% | -65.7% | -61.7% | -23.4% | -30.0% | -148.3% | -128.4% | -12.1% | -19.1% | -0.0% |
| ROA | -56.6% | -56.6% | -54.8% | -53.0% | -20.8% | -25.2% | -31.2% | -29.4% | -11.3% | -11.3% | -0.0% |
| ROIC | -64.9% | -64.9% | -107.1% | -261.9% | -106.4% | -98.4% | -62.4% | -160.7% | -5.0% | -4.0% | -0.0% |
| ROCE | -65.7% | -65.7% | -65.6% | -60.9% | -22.9% | -27.1% | -39.6% | -36.7% | -19.4% | -7.7% | -0.0% |
ACET Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $39M exceeds total debt of $15M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.09 | 0.09 | 0.12 | 0.07 | 0.07 | 0.20 | — | 0.03 | 7.12 | 0.39 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 10.03 |
| Net Debt / Equity | — | -0.15 | -0.21 | -0.82 | -0.81 | -0.85 | -0.57 | — | -0.04 | 6.04 | 0.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 4.39 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | 6.73 |
| Interest Coverage | -3392.06 | -3392.06 | -29279.50 | — | -871.38 | -351.98 | -293.72 | — | — | -4.83 | -0.00 |
Net cash position: cash ($39M) exceeds total debt ($15M)
ACET Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Adicet Bio, Inc.'s current ratio of 7.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 8.41x to 7.47x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.47 | 7.47 | 9.29 | 8.41 | 13.25 | 17.31 | 4.46 | 4.32 | 19.16 | 9.86 | 3.57 |
| Quick Ratio | 7.47 | 7.47 | 9.29 | 8.41 | 13.25 | 17.31 | 4.46 | 4.32 | 19.16 | -14.93 | 2.57 |
| Cash Ratio | 7.36 | 7.36 | 9.09 | 8.28 | 13.07 | 17.01 | 4.21 | 4.20 | 18.90 | 9.70 | 0.68 |
| Asset Turnover | — | — | — | — | 0.08 | 0.03 | 0.12 | 0.01 | 0.07 | 10.12 | 1.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | 0.00 | 4.19 |
| Days Sales Outstanding | — | — | — | — | 6.35 | 8.03 | 55.68 | 342.99 | — | — | 111.85 |
ACET Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Adicet Bio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $5M | $3M | $3M | $2M | $457499 | $1M | $2M | $2M | $2M |
Peer Comparison
Compare ACET with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACETYou | $75M | -0.5 | — | — | — | — | -67.6% | -64.9% | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CELC | $4B | -23.4 | — | — | — | — | -163.8% | -80.4% | — |
 TCRX | $118M | -0.9 | — | — | 72.2% | -1315.4% | -71.3% | -90.7% | — |
 IOVA | $1B | -3.7 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 ALLO | $463M | -2.2 | — | — | — | — | -53.4% | -41.2% | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 BEAM | $3B | -35.8 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
What if you invested $1,000 in ACET 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ACET be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ACET Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationACET vs FATE — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Fate Therapeutics, Inc..
Compare NowACET — Frequently Asked Questions
Quick answers to the most common questions about buying ACET stock.
What is Adicet Bio, Inc.'s P/E ratio?
Adicet Bio, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is Adicet Bio, Inc.'s ROE?
Adicet Bio, Inc.'s return on equity (ROE) is -67.6%. The historical average is -26.9%.
Is ACET stock overvalued?
Based on historical data, Adicet Bio, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.